Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Further therapy selections including bDMARDs, tsDMARDs, biosimilars or mixture therapy can be obtained when csDMARDs are ineffective or inadequately tolerated. bDMARDs are a more moderen selection for the therapy of RA and provide a https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/